Introduction Pulmonary vascular dysfunction, pulmonary hypertension (PH), and resulting
right ventricular (RV) failure occur in many critical illnesses and may be associated with a …

Inhaled nitric oxide (iNO) acts as a selective pulmonary vasodilator and it is currently
approved by the FDA for the treatment of persistent pulmonary hypertension of the newborn …

BACKGROUND: Treatment of postoperative pulmonary hypertension with intravenous (IV)
pulmonary vasodilators is hampered by the lack of selectivity. Inhaled nitric oxide produces …

Tissue from human corpus cavernosum contained high activities of PDE 2, 3, and 5,
whereas human cardiac ventricles mainly contained PDE 1, smaller peaks of PDE 2 and 3 …

Breathing low concentrations of nitric oxide (NO) produces selective pulmonary
vasodilatation and increases exercise capacity in patients with pulmonary hypertension of …

Persistent pulmonary hypertension of the newborn (PPHN) is a complex syndrome with
multiple causes, with an incidence of 0.43–6.8/1,000 live births and a mortality of 10–20 …

More than 30 million men are estimated to have erectile dysfunction (ED) in the United
States (Feldman et al. J Urol 1994; 151: 54–61). Worldwide, ED is estimated to affect more …

Acute right ventricular (RV) failure has until recently received relatively little attention in the
cardiology, critical care or anaesthesia literature. However, it is frequently encountered in …

Pulmonary hypertension frequently complicates the postoperative management of patients
after congenital cardiac surgery. Inhaled nitric oxide is an effective treatment option, but …

BACKGROUND: Pulmonary artery hypertension can complicate the early postoperative care
of patients with left ventricular assist devices (LVADs). Inhaled nitric oxide (INO) is frequently …